MedPath

Safety testing of cosmetic product by patch test on subjects with sensitive skin

Completed
Conditions
Adult subjects in the age group of 18 years to 55years (both inclusive) will be included
Registration Number
CTRI/2018/07/014697
Lead Sponsor
ITC Life Sciences Technology Centre
Brief Summary

The objective of this study is to evaluate the dermatological safety of the investigational products on healthy human subjects with sensitive skin.Primary irritation patch test is used widely for the evaluation of safety of cosmetics in humans.

Sample Size :Thirty Five (male and female, in a nearly ratio of 1:1) adult subjects in the age group of 18 years to 55 years (both inclusive)

Primary skin irritation results from reversible inflammatory changes in the skin following the application of a test substance.By this test, irritation potential of a substance is assessed by a single application of patch under

complete occlusion for 24 hrs and is done as per BIS standard (IS4011:1997) &IS 13424:2001

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Healthy male and female subjects in the age group of 18-55 years(both age inclusive) 2.
  • Subjects in good general health 3.
  • Subjects with Fitzpatrick skin type III to V 4.
  • Subjects scoring greater than 30 for Section 2- Sensitive v/s Resistant skin in modified Dr. Baumann’s skin type questionnaire 5.
  • Subject identified to have sensitive skin basis dermatologist’s assessment of skin with fine texture and closeness of blood vessels to the surface 6.
  • Subjects willing to give a voluntary written informed consent 7.
  • Subjects willing to maintain the test patches in designated positions for 24 hours 8.
  • Subjects having not participated in a similar investigation in the past eight weeks 9.
  • Subjects willing to come for regular follow up visits 10.
  • Subjects ready to follow instructions during the study period 11.
  • Subjects without any open wounds, cuts, abrasions, irritation symptoms.
Exclusion Criteria
  • Subjects with a present condition of allergic response to any cosmetic product 2.
  • Subjects under chronic medication (e.g. Antihistamines, Antifungals, Corticosteroids, topical Steroids, etc.) that might influence the outcome of the study 3.
  • Subjects who are pregnant or nursing (as confirmed by Urine pregnancy test for the determination of Pregnancy) 4.
  • Subjects with cutaneous disease that could interfere with the study results 5.
  • Subjects with chronic illness that may influence the cutaneous state or any other illness including Diabetes, liver disease, HIV or any other serious medical illness 6.
  • Subjects participating in any other cosmetic or therapeutic trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety assessment of investigational products forSafety assessment of investigational products for | irritation potential using Draize scale done on 0 | hour after patch removal, 24 hours after patch removal and 7 days post patch removal
irritation potential using Draize scaleSafety assessment of investigational products for | irritation potential using Draize scale done on 0 | hour after patch removal, 24 hours after patch removal and 7 days post patch removal
Secondary Outcome Measures
NameTimeMethod
Not ApplicableNot Applicable

Trial Locations

Locations (1)

CIDP Biotech India Pvt. Ltd.

🇮🇳

Central, DELHI, India

CIDP Biotech India Pvt. Ltd.
🇮🇳Central, DELHI, India
Dr Annie Jain
Principal investigator
011409793385
a.jain@cidp-cro.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.